Can new inodilators displace digitalis in the therapy of congestive heart failure?

Cardiovascular Drugs and Therapy
T Kumada, C Kawai

Abstract

New inodilators that possess both positive inotropic and vasodilator actions have many favorable effects in patients with congestive heart failure, even in those with refractory heart failure. These effects are expected to prevent myocardial injury, improve peripheral circulation, depress the excessive endogenous neurohumoral activation, and, finally, improve the quality of life, and increase lifespan. However, experience with new inodilators has only begun. Several questions remain to be answered before these drugs can be widely used with safety, including whether life-threatening adverse effects appear, mortality rate is lessened, and drug tolerance occurs. The therapeutic level of the dose and the relation between the effectiveness of the drug and the degree of the severity of heart failure should also be established. Therefore, long-term, randomized, double-blind, placebo-controlled clinical trials will be necessary before the new inodilators can take the place of digitalis and thus become the mainstay of the therapy of congestive heart failure.

References

Jan 1, 1978·Annual Review of Pharmacology and Toxicology·L I GoldbergJ D Kohli
Dec 21, 1978·The New England Journal of Medicine·A M Katz
Apr 1, 1977·The American Journal of Cardiology·T A GillespieR Roberts
Jul 22, 1985·The American Journal of Cardiology·D ManciniE Sonnenblick
Jan 11, 1985·The American Journal of Cardiology·G S Francis
Jan 30, 1986·The New England Journal of Medicine·J E MullerUNKNOWN MILIS Study Group
Jul 22, 1985·The American Journal of Cardiology·S H TaylorB Silke
Apr 1, 1970·Annals of Internal Medicine·S E EpsteinM Entman
Nov 1, 1973·The New England Journal of Medicine·T W Smith, E Haber
Aug 1, 1974·The American Journal of Physiology·S DavidsonE Braunwald
Dec 1, 1969·American Heart Journal·I Starr, R J Luchi
Oct 1, 1966·The Journal of Clinical Investigation·J W CovellE H Sonnenblick
Mar 1, 1983·Journal of Cardiovascular Pharmacology·L Dei CasO Visioli
Sep 1, 1984·Journal of Cardiovascular Pharmacology·J H RenC V Leier
Oct 3, 1980·European Journal of Pharmacology·J S KarlinerC Dollery
Jan 1, 1984·Annual Review of Pharmacology and Toxicology·A E FarahR P Schwarz
Aug 1, 1984·Journal of the American College of Cardiology·H Scholz
May 24, 1984·The New England Journal of Medicine·S I RajferL I Goldberg
Jul 1, 1981·The American Journal of Cardiology·K T WeberA P Fishman
Dec 1, 1981·Circulation·A J MossC L Odoroff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Related Papers

International Anesthesiology Clinics
Young Lan Kwak
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
Satyan Lakshminrusimha, Robin H Steinhorn
© 2022 Meta ULC. All rights reserved